drugset / Trial / NCT07374445

Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery

NCT07374445

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to compare the weight loss and metabolic benefit in patients remaining obesity at 6 months after metabolic surgery. The main questions it aims to answer are: \[primary hypothesis 1\] Whether liraglutide benefits weight loss when it is initiated early after metabolic surgery. \[primary hypothesis 2\] Whether weight loss and metabolic benefits are greater when linaglutide is initiated in patients who are obese at 6 months after metabolic surgery

Timeline

Start
2023-09-01
Primary completion
2025-06-01
Completion
2025-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 3 mg Other

Indications